VitaDX is pleased to be one the companies in Britain to have raised funds in the last 2 years to finance their development.
Wednesday January 11th, 2017
Monday January 9th, 2017
Thursday January 5th, 2017
VitaDX launches today its first clinical trial VisioCyt 1. This multicentric study on 1300 patients aims to evaluate the diagnostic performances of the VisioCyt® test.